Financhill
Buy
62

COO Quote, Financials, Valuation and Earnings

Last price:
$91.47
Seasonality move :
10.1%
Day range:
$91.91 - $93.44
52-week range:
$84.76 - $112.38
Dividend yield:
0%
P/E ratio:
47.45x
P/S ratio:
4.76x
P/B ratio:
2.28x
Volume:
961K
Avg. volume:
1.6M
1-year change:
-0.89%
Market cap:
$18.5B
Revenue:
$3.9B
EPS (TTM):
$1.95

Analysts' Opinion

  • Consensus Rating
    The Cooper Companies has received a consensus rating of . The company's average rating is a based on 9 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $112.01, The Cooper Companies has an estimated upside of 21.06% from its current price of $92.52.
  • Price Target Downside
    According to analysts, the lowest downside price target is $90.00 representing 100% downside risk from its current price of $92.52.

Fair Value

  • According to the consensus of 0 analysts, The Cooper Companies has 21.06% upside to fair value with a price target of $112.01 per share.

COO vs. S&P 500

  • Over the past 5 trading days, The Cooper Companies has underperformed the S&P 500 by -3.23% suggesting its relative strength compared to the major market average is weak at this time.

Share Buyback

  • The Cooper Companies does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • The Cooper Companies has grown year-over-year revenues for 16 quarters straight. In the most recent quarter The Cooper Companies reported revenues of $1B.

Earnings Growth

  • The Cooper Companies has grown year-over-year earnings for 3 quarters straight. In the most recent quarter The Cooper Companies reported earnings per share of $0.58.
Enterprise value:
20.9B
EV / Invested capital:
1.96x
Price / LTM sales:
4.76x
EV / EBIT:
30.06x
EV / Revenue:
5.38x
PEG ratio (5yr expected):
1.52x
EV / Free cash flow:
72.68x
Price / Operating cash flow:
64.36x
Enterprise value / EBITDA:
19.54x
Gross Profit (TTM):
$2.6B
Return On Assets:
3.26%
Net Income Margin (TTM):
10.07%
Return On Equity:
5.02%
Return On Invested Capital:
3.75%
Operating Margin:
19.48%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-10-31 2023-10-31 2024-10-31 2023-10-31 2024-10-31
Income Statement
Revenue $3.3B $3.6B $3.9B $927.1M $1B
Gross Profit $2.1B $2.4B $2.6B $606.5M $677.7M
Operating Income $507.6M $533.1M $705.7M $135.7M $198.4M
EBITDA $878.7M $885.9M $1.1B $225.4M $286.6M
Diluted EPS $1.94 $1.49 $1.95 $0.43 $0.58
Period Ending 2020-10-31 2021-10-31 2022-10-31 2023-10-31 2024-10-31
Balance Sheet
Current Assets $1.3B $1.5B $1.5B $1.7B $2B
Total Assets $6.7B $9.6B $11.5B $11.7B $12.3B
Current Liabilities $1B $732.1M $1.3B $969M $1B
Total Liabilities $2.9B $2.7B $4.3B $4.1B $4.2B
Total Equity $3.8B $6.9B $7.2B $7.6B $8.1B
Total Debt $1.8B $1.5B $2.7B $2.6B $2.6B
Trailing 12 Months Fiscal Quarters
Period Ending 2022-10-31 2023-10-31 2024-10-31 2023-10-31 2024-10-31
Cash Flow Statement
Cash Flow Operations $692.4M $607.5M $709.3M $174.2M $268.1M
Cash From Investing -$1.8B -$449M -$764.6M -$160.8M -$241.6M
Cash From Financing $1.2B -$173.9M $39.2M -$6.5M -$28.4M
Free Cash Flow $450.4M $215M $288.1M $29.2M $128.1M
COO
Sector
Market Cap
$18.5B
$45.6M
Price % of 52-Week High
82.33%
45.55%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.74%
1-Year Price Total Return
-0.89%
-31.35%
Beta (5-Year)
0.968
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Sell
Level $93.79
200-day SMA
Sell
Level $97.94
Bollinger Bands (100)
Sell
Level 96.1 - 108.36
Chaikin Money Flow
Buy
Level 166.6M
20-day SMA
Sell
Level $98.70
Relative Strength Index (RSI14)
Sell
Level 30.48
ADX Line
Buy
Level 9.74
Williams %R
Buy
Level -91.5639
50-day SMA
Sell
Level $101.98
MACD (12, 26)
Sell
Level -2.77
25-day Aroon Oscillator
Sell
Level -44
On Balance Volume
Neutral
Level 71.5M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (4.3823)
Buy
CA Score (Annual)
Level (0.6224)
Buy
Beneish M-Score (Annual)
Level (-2.4375)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.9894)
Buy
Piotroski F Score (Annual)
Level (9)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (8)

Revenue Forecast

Earnings per Share Forecast

Company Profile

CooperCompanies is one of the largest eyecare companies in the us. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the us contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women’s care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the us, and controls 17% of the us IUD market.

Stock Forecast FAQ

In the current month, COO has received 9 Buy ratings 7 Hold ratings, and 0 Sell ratings. The COO average analyst price target in the past 3 months is $112.01.

  • Where Will The Cooper Companies Stock Be In 1 Year?

    According to analysts, the consensus estimate is that The Cooper Companies share price will rise to $112.01 per share over the next 12 months.

  • What Do Analysts Say About The Cooper Companies?

    Analysts are divided on their view about The Cooper Companies share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that The Cooper Companies is a Sell and believe this share price will drop from its current level to $90.00.

  • What Is The Cooper Companies's Price Target?

    The price target for The Cooper Companies over the next 1-year time period is forecast to be $112.01 according to 0 Wall Street analysts, 9 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.

  • Is COO A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for The Cooper Companies is a . 0 of 0 analysts rate the stock a at this time.

  • How Can I Buy Shares Of COO?

    You can purchase shares of The Cooper Companies via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase The Cooper Companies shares.

  • What Is The The Cooper Companies Share Price Today?

    The Cooper Companies was last trading at $91.47 per share. This represents the most recent stock quote for The Cooper Companies. Yesterday, The Cooper Companies closed at $92.52 per share.

  • How To Buy The Cooper Companies Stock Online?

    In order to purchase The Cooper Companies stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Alphabet an Undervalued Growth Stock to Buy?
Is Alphabet an Undervalued Growth Stock to Buy?

Alphabet (NASDAQ:GOOGL) is easily one of the most successful companies…

Is Tesla Going to Buy Uber?
Is Tesla Going to Buy Uber?

Tesla has always been in the habit of making large,…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

If you want to invest in an AI-leading tech company,…

Stock Ideas

Buy
65
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
57
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 117x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Sell
40
MSTR alert for Dec 24

MicroStrategy [MSTR] is up 7.46% over the past day.

Sell
26
NUTX alert for Dec 24

Nutex Health [NUTX] is down 0.76% over the past day.

Sell
48
VRNA alert for Dec 24

Verona Pharma PLC [VRNA] is down 0.62% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock